Long-term follow-up of Galapagos CAR T-cell therapy recipients
Part of Blood & lymphatic, Cancer clinical trials.
This study is for people who have already received a specific type of cell therapy (CAR T-cell therapy) made by Galapagos. It will follow them over the long term to see how they are doing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have already received a Galapagos CAR T-cell therapy in a previous clinical trial or managed access program.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with blood cancers who are treated with CAR-T cell therapy. Researchers will follow participants over time to learn more about how this therapy works in the real world.
This study is for people who previously received CAR T cells at the Dana-Farber/Harvard Cancer Center (DF/HCC). It mainly checks how you’re doing over the long term after treatment, and asks you to take part in follow-up visits or procedures.
This study monitors participants who received a certain type of CAR T-cell therapy for cancer. It helps researchers understand long-term effects and safety.
This study follows people who have already received a CRISPR CAR T cell therapy to monitor their long-term health and any side effects. It helps doctors understand how these treatments work over time.
This study follows patients who received gene therapy at Seattle Children's Hospital to check on their health and safety over time. It helps doctors understand how well the treatment works in the long run.
This study checks how people do over the long run after receiving a personalized, genetically modified CAR T cell treatment. It may help researchers understand long-term safety and outcomes, which can improve future care.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.